Scholar Rock Holding Stock Price, News & Analysis

Scholar Rock (NASDAQ: SRRK) has announced an e-poster presentation of clinical results from the TOPAZ Phase 2 trial of apitegromab for Type 2 and 3 spinal muscular atrophy (SMA) during the 25th World Congress of Neurology (WCN) from October 3-7, 2021. The presentation shows positive correlations between serum levels of latent myostatin and motor function improvements. Apitegromab is a selective myostatin inhibitor with FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations, but its efficacy and safety have yet to be established.

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company, announces a late-breaking poster presentation at the 50th Child Neurology Society Annual Meeting held from September 29 to October 2, 2021, in Boston. The presentation focuses on the efficacy of Apitegromab in patients with later-onset Spinal Muscular Atrophy (SMA) Types 2 and 3, highlighting responder analyses from the Phase 2 TOPAZ study. The poster will be published in the 2021 Annals of Neurology supplement. Apitegromab has received multiple designations from the FDA and EMA, although its efficacy and safety are not yet established.

Scholar Rock (NASDAQ: SRRK) announced the issuance of U.S. Patent No. 11,130,803, expiring May 2040, for SRK-181, a selective TGFβ1 inhibitor aimed at treating patients resistant to checkpoint inhibitors like anti-PD-(L)1 therapies. This patent fortifies the company's intellectual property as it progresses in the DRAGON Phase 1 trial, which focuses on safety and effectiveness in various solid tumor types. Initial clinical data from the trial is expected by year-end, reinforcing Scholar Rock's commitment to developing innovative cancer treatments.

Scholar Rock (NASDAQ: SRRK) recently presented two posters at the World Muscle Society Virtual Congress from September 20-24, 2021. The presentations highlighted findings from the TOPAZ Phase 2 trial of apitegromab for treating Spinal Muscular Atrophy (SMA). Key results include improvements in various efficacy endpoints such as Hammersmith scales and Revised Upper Limb Module (RULM) scores among patients. This research supports the potential of apitegromab and sets the stage for a Phase 3 trial aimed at establishing it as a leading muscle-directed therapy for SMA by year-end 2021.

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company, has announced its upcoming presentation at the 2021 Cantor Virtual Global Healthcare Conference on September 29 at 11:20 a.m. ET. This event marks an opportunity for the company to showcase its innovative approach in treating serious diseases through targeted protein growth factors. Interested parties can access the live webcast via the Scholar Rock website, with an archived replay available for 90 days post-event.

Scholar Rock (NASDAQ: SRRK) announces the appointment of Caryn Parlavecchio as the new Chief Human Resources Officer. With over 20 years of experience in the biotechnology and pharmaceutical sectors, she will enhance the company's HR strategies and talent acquisition efforts. Interim CEO Nagesh Mahanthappa emphasized that her insights will be pivotal for Scholar Rock's growth as it moves towards late-stage development and commercialization. Parlavecchio previously served at Holy Name Medical and held significant roles at Novartis.

Scholar Rock (NASDAQ: SRRK) reported a net loss of $30.7 million for Q2 2021, compared to a $19.3 million loss in Q2 2020. Revenue increased to $4.6 million, driven by the Gilead collaboration.

The company highlighted progress in its pipeline, particularly with apitegromab in spinal muscular atrophy (SMA), showing improvements in motor function in the Phase 2 TOPAZ trial. A Phase 3 trial is expected by year-end. SRK-181 is progressing through the DRAGON trial aimed at overcoming resistance in solid tumors. Scholar Rock has $282 million in cash, supporting its ongoing clinical programs.

Scholar Rock (NASDAQ: SRRK) announced its participation in the 2021 Wedbush PacGrow Healthcare Conference on August 11, 2021, at 9:10 a.m. ET. Interested parties can access a live webcast through the Investors & Media section of its website. An archived version will be available for 90 days post-presentation. The company focuses on treating serious diseases related to protein growth factors, developing novel therapies for conditions such as neuromuscular disorders, cancer, and fibrosis. More information can be found at scholarrock.com.

Scholar Rock (NASDAQ: SRRK) has announced the departure of CEO Tony Kingsley and his resignation from the Board of Directors. Nagesh Mahanthappa, the company's founder, will serve as Interim CEO while a search for a permanent successor is conducted. The Board expresses confidence in Mahanthappa's experience to ensure a seamless leadership transition. Scholar Rock remains focused on advancing its clinical pipeline, including the Phase 3 trial for apitegromab in spinal muscular atrophy and the DRAGON Phase 1 trial for SRK-181.